2016 Related Topics 
Fierce Pharma
SEPTEMBER 16, 2024
Looking to assess whether Ocaliva met its postmarketing requirements after a 2016 accelerated approval in the autoimmune disease primary biliary cholangitis, an FDA council of outside experts nearly unanimously rejected Intercept’s hopes for a full approval.
Fierce Pharma
SEPTEMBER 11, 2024
The regulator specifically raised an eyebrow at the post-marketing trials Intercept has used in a bid to keep hold of the accelerated approval it won back in 2016.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 20, 2023
When Sanofi made an asset swap with Boehringer Ingelheim in 2016, the French company acquired BI’s healthcare business, which included heartburn medicine Zantac. | In an asset swap with Boehringer in 2016, Sanofi gained U.S. marketing rights to the treatment.
Fierce Pharma
OCTOBER 18, 2023
The accusations centered on the company's compensation of 86 female employees in 2015 and 2016. Department of Labor that it underpaid certain women who were employed at the company’s New York City headquarters. |
Fierce Pharma
SEPTEMBER 28, 2023
Bluebird and Lonza recently amended their production contract for the second time since the deal was announced in summer of 2016. As bluebird bio’s pricey gene therapy launches take flight, the company is boosting manufacturing capacity with Swiss CDMO Lonza.
pharmaphorum
JUNE 27, 2016
As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year.
Fierce Pharma
JUNE 8, 2023
Novartis’ generics and biosimilars unit Sandoz—soon to be spun off as a stand-alone company—has seen a decline | Novartis’ generics and biosimilars unit Sandoz—soon to be spun off as a stand-alone company—has seen a decline in revenue every year since 2016.
Expert insights. Personalized for you.
223 
Let's personalize your content